

# SCIENTIFIC REPORTS



OPEN

## Anti-tumour activity of tivozanib, a pan-inhibitor of VEGF receptors, in therapy-resistant ovarian carcinoma cells

Received: 25 August 2016

Accepted: 08 March 2017

Published: 06 April 2017

Majid Momeny<sup>1,\*</sup>, Zahra Sabourinejad<sup>2,3,\*</sup>, Ghazaleh Zarrinrad<sup>1,\*</sup>, Farima Moghaddaskho<sup>1</sup>, Haniyeh Eyvani<sup>1</sup>, Hassan Yousefi<sup>4</sup>, Shahab Mirshahvaladi<sup>5</sup>, Ensieh M. Poursani<sup>1</sup>, Farinaz Barghi<sup>1</sup>, Arash Poursheikhani<sup>4</sup>, Leila Dardaei<sup>6</sup>, Davood Bashash<sup>7</sup>, Mahmoud Ghazi-Khansari<sup>8</sup>, Seyyed M. Tavangar<sup>2</sup>, Ahmad R. Dehpour<sup>8,9</sup>, Marjan Yaghmaie<sup>1</sup>, Kamran Alimoghaddam<sup>1</sup>, Ardeshir Ghavamzadeh<sup>1</sup> & Seyed H. Ghaffari<sup>1</sup>

Epithelial ovarian cancer (EOC) is the most fatal gynaecological malignancy. Despite initial therapeutic response, the majority of advanced-stage patients relapse and succumb to chemoresistant disease. Overcoming drug resistance is the key to successful treatment of EOC. Members of vascular endothelial growth factor (VEGF) family are overexpressed in EOC and play key roles in its malignant progression though their contribution in development of the chemoresistant disease remains elusive. Here we show that expression of the VEGF family is higher in therapy-resistant EOC cells compared to sensitive ones. Overexpression of *VEGFR2* correlated with resistance to cisplatin and combination with *VEGFR2*-inhibitor apatinib synergistically increased cisplatin sensitivity. Tivozanib, a pan-inhibitor of VEGF receptors, reduced proliferation of the chemoresistant EOC cells through induction of G2/M cell cycle arrest and apoptotic cell death. Tivozanib decreased invasive potential of these cells, concomitant with reduction of intercellular adhesion molecule-1 (ICAM-1) and diminishing the enzymatic activity of urokinase-type plasminogen activator (uPA) and matrix metalloproteinase-2 (MMP-2). Moreover, tivozanib synergistically enhanced anti-tumour effects of EGFR-directed therapies including erlotinib. These findings suggest that the VEGF pathway has potential as a therapeutic target in therapy-resistant EOC and VEGFR blockade by tivozanib may yield stronger anti-tumour efficacy and circumvent resistance to EGFR-directed therapies.

Epithelial ovarian cancer (EOC) is the fifth most common cause of cancer death among women worldwide. It is estimated that approximately 22000 women are diagnosed with EOC in the United States and 14000 patients die from this disease each year<sup>1</sup>. Late-stage diagnosis, peritoneal metastasis and frequent development of chemoresistance restrain improvements in overall survival rate. First-line treatment for EOC includes debulking surgery followed by taxane/platinum-based regimens. Despite promising initial response, the majority of patients with advanced disease relapse and exhibit resistance to both chemotherapeutics and targeted therapies<sup>2</sup>.

<sup>1</sup>Haematology/Oncology and Stem Cell Transplantation Research Centre, Shariati Hospital, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran. <sup>2</sup>Department of Pathology, Shariati Hospital, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran. <sup>3</sup>Islamic Azad University, East Tehran Branch, Tehran, Iran. <sup>4</sup>Department of Medical Genetics, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran. <sup>5</sup>Department of Molecular Systems Biology, Cell Science Research Centre, Royan Institute for Stem Cell Biology and Technology, Tehran, Iran. <sup>6</sup>Massachusetts General Hospital Cancer Centre, Charlestown, MA, USA. <sup>7</sup>Department of Haematology and Blood Banking, Faculty of Allied Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran. <sup>8</sup>Department of Pharmacology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran. <sup>9</sup>Experimental Medicine Research Centre, Tehran University of Medical Sciences, Tehran, Iran. \*These authors contributed equally to this work. Correspondence and requests for materials should be addressed to S.H.G. (email: shghaffari200@yahoo.com)

Chemosensitivity (IC <sub>50</sub> ) <sup>a</sup>								
Cell Lines	Cisplatin (µg/mL)	Carboplatin (µg/mL)	Paclitaxel (µg/mL)	Doxorubicin (ng/mL)	Vincristine (ng/mL)	Gemcitabine (ng/mL)	Erlotinib (µM)	Cetuximab (µg/mL)
OVCAR3	1.025	797	2	432	>1000	154	64	>100
SKOV3	5.8	71	5.4	696	>1000	24	114	>100
A2780CP	1.145	51	1.4	600	37	27	10.3	>100
A2780S	0.8634	4.6	0.2	4.1	32	16	5.2	82
Caov4	0.3	2.7	0.1	5.1	3.4	4.6	2.6	44

**Table 1. Chemosensitivities of a panel of EOC cell lines to certain chemotherapeutics and targeted therapies.** <sup>a</sup>Chemosensitivity is expressed as IC<sub>50</sub> for each cell line, which is the concentration of drug that caused a 50% reduction in proliferation compared to vehicle-treated cells.

Intrinsic and acquired resistance to chemotherapy are responsible for treatment failure in EOC<sup>3</sup>. Patients with the recurrent disease are treated with agents such as gemcitabine but clinical trials report that the median overall survival is still dismal<sup>4</sup>. There is, therefore, a pressing need to devise more efficacious treatments to overcome chemoresistance mechanisms and improve the outcome of EOC patients.

Angiogenesis, a multi-step process by which tumours develop new vasculature, is essential for tumour growth and metastasis<sup>5</sup>. The vascular endothelial growth factor (VEGF)/VEGF receptor (VEGFR) signalling pathway is the most promising angiogenic target due to its key roles in angiogenesis and tumour growth<sup>6,7</sup>. The VEGF family consists of seven ligands including VEGFA, VEGFB, VEGFC, VEGFD, VEGFE, placenta growth factor (PlGF) 1, and PlGF2. The tyrosine kinase receptors in this family include VEGFR type 1 (VEGFR1), VEGFR2 and VEGFR3<sup>6</sup>. Synthesized VEGF mimicking peptides have also been shown to bind to VEGF receptors, initiate VEGF-induced signalling and stimulate angiogenesis<sup>8</sup>.

Elevated expression of the VEGF ligands and receptors promotes malignant progression and correlates with poor prognosis in EOC<sup>9,10</sup>. High expression of VEGFA associates with advanced stage disease, development of malignant ascites and acquisition of an invasive phenotype<sup>11</sup>. Increased expression of VEGFC and VEGFR2 correlates with lymph node metastasis and peritoneal dissemination, a frequent cause of death in patients with primary advanced or recurrent EOC<sup>12,13</sup>. In this setting, blocking VEGFA activity in murine models of EOC halts tumour growth and ascites formation<sup>14</sup>. Altogether, these studies suggest that the VEGF family is importantly implicated in pathogenesis of EOC by influencing tumour growth and metastasis (via driving angiogenesis) and ascites formation (through stimulation of vascular permeability)<sup>15</sup>.

Evidence indicates that targeting angiogenesis is an effective therapeutic strategy in EOC and anti-angiogenic agents are among the most successful targeted therapies in this malignancy<sup>16,17</sup>. Patients treated with bevacizumab (anti-VEGFA mAb) alone or in combination with cytotoxic chemotherapies have demonstrated improvements in progression-free survival<sup>18,19</sup>. Addition of bevacizumab to several cytotoxic regimens improves response rate in patients with recurrent platinum-resistant disease<sup>20,21</sup>. While early clinical studies have determined remarkable activity of bevacizumab, lack of improvement in overall survival, considerable toxicity, frequent development of resistance, absence of a predictive biomarker and high cost of bevacizumab therapy highlight the need to establish novel and more efficacious anti-angiogenesis therapy in EOC<sup>17,22</sup>.


Tivozanib is a pan-VEGFR tyrosine kinase inhibitor that hampers angiogenesis and vascular permeability in tumour tissues<sup>23</sup>. Tivozanib has shown anti-tumour activities in xenograft models of colon, breast, lung, prostate, pancreas, glioblastoma and renal cell carcinoma<sup>24,25</sup>. In a phase I study in patients with advanced solid tumours, it has been found to be well tolerable with manageable side effects and durable clinical activity<sup>26</sup>. Tivozanib is currently under investigation in a phase II study in recurrent platinum-resistant ovarian cancer (NCT01853644)<sup>27</sup>. In the present study, we examined the mechanistic activity of tivozanib in therapy-resistant EOC cell lines.

## Results

**Chemosensitivity of the EOC cell lines.** The sensitivity of a panel of EOC cell lines to certain chemotherapeutic agents and targeted therapies were determined by MTT assay and are summarized in Table 1. These data show that OVCAR3, SKOV3 and A2780CP cells exhibit multidrug-resistant behaviour. Moreover, A2780S and Caov4 cells show sensitivity to carboplatin, paclitaxel, doxorubicin, gemcitabine, erlotinib and cetuximab (Table 1, Supplementary Fig. 1).

**Expression of the VEGF family in the EOC cells.** The expression of VEGF ligands and receptors in chemoresistant versus chemosensitive EOC cells is not yet examined. To explore potential association between chemoresponsiveness and expression of the VEGF family, their relative expression was investigated by qRT-PCR. This screening experiment revealed that the expression of *VEGFA*, *VEGFC*, *VEGFD*, *VEGFR1* and *VEGFR2* is higher in multidrug-resistant OVCAR3, SKOV3 and A2780CP cells compared to the chemosensitive ones (Fig. 1A,B).

The elevated expression of the VEGF family in the therapy-resistant EOC cells prompted us to examine possible correlation between their mRNA levels and chemoresponsiveness. We found that higher expression of *VEGFR2* associates with resistance to cisplatin by Pearson's correlation (Fig. 1C). The correlation coefficient ( $r$ ) between the *VEGFR2* expression and cisplatin concentrations was 0.8876 ( $P = 0.0404$ ). To further confirm that *VEGFR2* may contribute to cisplatin resistance, we determined the effects of apatinib, a *VEGFR2* specific




**Figure 1. Expression of the VEGF family in the EOC cells. (A,B).** Higher expression of *VEGFA*, *VEGFC*, *VEGFD*, *VEGFR1* and *VEGFR2* was observed in the multidrug-resistant OVCAR3, SKOV3 and A2780CP cells compared to the chemosensitive cell lines. Gene expression levels were normalized to *HPRT1* (C) Correlation of *VEGFR2* expression with resistance to cisplatin. EOC cell lines with higher expression of *VEGFR2* showed significantly higher cisplatin  $IC_{50}$  values. (D) The effect of the time-sequenced apatinib-cisplatin therapy on cell proliferation was investigated by MTT assay and shown by  $IC_{50}$  shift analysis. The cultures were pre-treated with apatinib (10  $\mu$ M) followed by treatment with cisplatin (0.1, 0.5, 1, 2.5, 5 and 10  $\mu$ g/mL) for 48 h. (E) The effect of apatinib-cisplatin therapy on cell viability was demonstrated by crystal violet staining. The cells were pre-treated with apatinib (10  $\mu$ M) followed by treatment with 0.1  $\mu$ g/mL of cisplatin for 48 h. The cultures were stained with crystal violet and imaged by an inverted microscope (images acquired at 10x magnification). (F) Normalised isobolograms of combination of apatinib and cisplatin. The data were analysed using the CalcuSyn software. The connecting line represents additivity. Data points located below the line indicate a synergistic drug-drug interaction and data points above the line indicate an antagonistic interaction. The numbers under the isobolograms indicate the doses of cisplatin and apatinib in combination. (G) Association of *VEGFC* expression and resistance to erlotinib. Higher expression of *VEGFC* ( $r=0.93$ ,  $P=0.02$ ) positively correlated with resistance to erlotinib. (H) The effect of exogenous VEGFC on proliferative response to erlotinib was determined by MTT assay. Caov4 cells were pre-treated with human recombinant VEGFC (rVEGFC) for 4 h, followed by treatment with erlotinib for 48 h. Data are given as mean  $\pm$  SD. Statistically significant values of  $*p < 0.05$ ,  $**p < 0.01$ , and  $***p < 0.001$  were determined compared with the control.

inhibitor, on proliferative response of the chemoresistant EOC cells to cisplatin. For the combination therapy, we followed a time-staggered treatment protocol as described by Lee *et al.*<sup>28</sup>. The cells were pre-treated with apatinib for 4 h, followed by treatment with cisplatin for 48 h. Combination with apatinib synergistically increased sensitivity to cisplatin (Fig. 1D–F, Supplementary Table 1).

We also found a positive correlation between erlotinib resistance and higher expression of *VEGFC* (Fig. 1G). Moreover, pre-treatment with human recombinant VEGFC (10 ng/mL) decreased anti-proliferative effects of erlotinib in the chemosensitive Caov4 cells (Fig. 1H). Altogether, these data suggest that VEGFR2 and VEGFC might contribute to resistance to cisplatin and erlotinib, respectively.

**Tivozanib inhibits proliferation, clonogenic potential and anoikis resistance.** MTT assay was carried out to determine the effect of tivozanib on proliferation of the therapy-resistant EOC cells. Treatment of these cells with tivozanib reduced their proliferation (Fig. 2A). Moreover, tivozanib diminished their clonogenic growth (Fig. 2B,C). In immortalized cells, detachment from the extracellular matrix induces anoikis, a special type of apoptosis<sup>29</sup>. Acquisition of resistance to anoikis is a prerequisite for EOC cells to survive in the ascites before forming metastatic foci<sup>30</sup>. Using an anoikis resistance assay, we found that tivozanib reduced surviving fraction of the EOC cells (Fig. 2D). Tivozanib decreased the expression of the anoikis resistance marker *BCL2*<sup>31</sup>, suggesting that the diminished surviving fraction by tivozanib is due to enhanced anoikis (Fig. 2E).

**Tivozanib induces G2/M cell cycle arrest and apoptosis.** Due to the anti-proliferative effects of tivozanib, we asked if tivozanib inhibits cell cycle progression or affects apoptosis. In OVCAR3 and A2780CP cells, tivozanib increased the percentage of cells in G2/M phase while decreasing the G1/S fraction. Moreover, a small number of cells underwent apoptotic cell death, as indicated by appearance of a sub-G0/G1 population. SKOV3 cells treated with tivozanib displayed an increase in the G2/M population (Fig. 3A).



**Figure 2. Tivozanib inhibits proliferation, clonal growth and anoikis resistance.** (A) The effect of tivozanib on cell viability was estimated by MTT assay. (B,C) Clonogenic assay was conducted to evaluate the effect of tivozanib on clonal proliferation. (D) Anoikis resistance assay was performed with cell culture on poly-HEMA-coated culture dishes for 48 h and the proportion of viable cells was measured by MTT assay. (E) qRT-PCR was carried out to determine whether tivozanib-mediated decrease in the surviving fraction is due to down-regulation of the anoikis resistance marker *BCL2*. Gene expression levels were normalized to *HPRT1*. Data are given as mean  $\pm$  SD, normalized to the vehicle-treated control group. Statistically significant values of \* $p < 0.05$ , \*\* $p < 0.01$ , and \*\*\* $p < 0.001$  were determined compared with the control.

We next determined the effects of tivozanib on expression of genes and proteins that regulate the G2/M transition. Activation of Cdc2/cyclin B kinase complex is a pivotal step in mitotic initiation. Wee1 and myelin transcription factor 1 (encoded by *MYT1*) are cell cycle-regulated kinases that block mitotic entry via phosphorylation of Cdc2 while Cdc25C dephosphorylates Cdc2 and permits entry into mitosis<sup>32,33</sup>. Checkpoint kinase 2 (encoded by *CHEK2*) is a putative tumour suppressor that prevents mitotic progression by inhibiting Cdc25C<sup>34</sup>.

Tivozanib decreased both Cdc25C and cyclin B1 protein expression (Fig. 3B, Supplementary Fig. 2). Both mRNA and protein levels of the G2/M checkpoint regulator p21 (encoded by *CDKN1A*) were increased following tivozanib treatment (Fig. 3B,C, Supplementary Fig. 2). Moreover, tivozanib increased the mRNA levels of *WEE1*, *MYT1* and *CHEK2* (Fig. 3C). These data show that tivozanib inhibits proliferation of the EOC cells through a G2/M cell cycle arrest and induction of apoptosis.


**Tivozanib reduces invasive abilities of the EOC cells.** Interplays between the VEGF pathway and extracellular proteinases including urokinase plasminogen activator (uPA) and matrix metalloproteinases (MMPs) are implicated in peritoneal spread of EOC cells<sup>35</sup>. Evidence indicates that the VEGF/VEGFR loop drives EOC invasion through induction of uPA and MMP-2<sup>36,37</sup>. Conversely, MMP-2 contributes to release of biologically active VEGFA and ascites formation<sup>38</sup>. Our findings show that tivozanib reduced enzymatic levels of uPA and MMP-2 (Fig. 4A,B, Supplementary Fig. 3).

The VEGF/VEGFR pathway has been shown to promote metastatic dissemination of EOC cells<sup>39,40</sup>. We next determined if tivozanib-mediated inhibition of uPA and MMP-2 associates with attenuation of migration and invasion in the EOC cells. Using Transwell assays, the resulting data demonstrate that tivozanib diminished migratory and invasive behaviour of these cells (Fig. 4C,D).


A major route for the metastatic spread of EOC cells is by attachment to the mesothelium lining in the peritoneal cavity, a critical step to establish foci and penetrate the underlying stroma<sup>41</sup>. To investigate whether tivozanib attenuates adhesive properties of the EOC cells, we assayed adhesion of tivozanib-treated cells to collagen I which is a substrate for a range of cell adhesion molecules. Tivozanib reduced adhesion of these cells to collagen I, concomitant with suppression of intercellular adhesion molecule-1 (ICAM-1) (Fig. 4E–G), a cell surface adhesion molecule that mediates tumour cell binding to the mesothelium and enhances tumour invasion<sup>42,43</sup>.

**Effects of tivozanib on VEGFR2, AKT, ERK1/2 and NF- $\kappa$ B pathways.** The VEGF/VEGFR pathway causes a cascade of downstream events including activation of Ras/MEK/ERK axis<sup>44</sup>. In ovarian carcinoma tissues, activation of STAT3 correlates with expression of VEGFA, VEGFR1 and VEGFR2<sup>45</sup>. In addition, a positive association between expression of VEGFR2 and AKT activation has been demonstrated in EOC clinical samples<sup>46</sup>. Western blot analysis was applied to explore the effects of tivozanib-mediated inhibition of p-VEGFR2 on AKT, ERK1/2, STAT3 and NF- $\kappa$ B pathways. Tivozanib at higher doses attenuated AKT, ERK1/2 and NF- $\kappa$ B pathways in OVCAR3 and A2780CP cells. In comparison, tivozanib treatment induced p-ERK1/2 in SKOV3 cells, suggesting that ERK1/2 activation might be a compensatory mechanism for inhibition of VEGFR signalling in these cells (Fig. 5).


**Synergistic activity of tivozanib with EGFR-targeted therapies.** EGFR overexpression occurs in 35–70% of EOC patients<sup>47</sup>. Preclinical data suggest that resistance to anti-EGFR targeted therapies results from increased tumour angiogenesis<sup>48</sup>. We therefore asked if VEGFR blockade by tivozanib increases sensitivity to



**Figure 3. Tivozanib induces G2/M cell cycle arrest and apoptosis.** (A) Following treatment with tivozanib for 48 h, the cell pellets were fixed and incubated with propidium iodide to analyse the cell cycle distribution on a flow cytometer. The concentrations of tivozanib were 2, 5, 10 and 20  $\mu$ M. The graphs are representative of three independent experiments with similar results. (B) Protein lysates from tivozanib-treated cells were subjected to Western blotting and probed with the indicated antibodies.  $\beta$ -actin was used as the loading control. The blots are representative of three independent experiments with similar outcomes. (C) The cells were treated with tivozanib for 48 h then total RNA was harvested for qRT-PCR analysis. Gene expression levels were normalized to *HPRT1*. Data are given as mean  $\pm$  SD. Statistically significant values of  $*p < 0.05$ ,  $**p < 0.01$ , and  $***p < 0.001$  were determined compared with the control. *IL*, interleukin; *CDKN1A*, cyclin-dependent kinase inhibitor 1 A; *CCNB1*, cyclin B1; *CDK*, cyclin-dependent kinase; *GADD45A*, growth arrest and DNA damage inducible alpha; *CHEK*, checkpoint kinase; *CDC25*, cell division cycle 25; *CCNA2*, cyclin A2; *MYT1*, myelin transcription factor 1; *SFN*, stratifin.



**Figure 4.** (A) Tivozanib inhibits uPA activity. The cells were treated with tivozanib for 48 h and equal amounts of total secreted protein from each sample were subjected to a chromogenic substrate, which is cleaved by active uPA and produces a colorimetrically detectable product. (B) Tivozanib inhibits enzymatic levels of MMP-2. The conditioned media from tivozanib-treated cells was separated on a non-reducing polyacrylamide gel containing gelatin A. Gelatinolytic activities are visualized as clear bands against the blue background of stained gelatin. The concentrations of tivozanib were 2, 5, 10 and 20  $\mu$ M. The zymograms are representative of three independent experiments with similar results. The gels were cropped and the full-length gels are presented in Supplementary Fig. 3 (C,D) Tivozanib hinders migration and invasion. The cells were placed into 8- $\mu$ m porous culture inserts, treated with tivozanib and allowed to migrate for 48 h. The migrated cells on the lower surface of the inserts were quantified by crystal violet staining. For invasion assay, the cells were placed into matrigel-coated inserts and allowed to invade through the matrigel layer for 48 h. (E) Tivozanib decreases adhesive potential of the EOC cells. Tivozanib-treated cells were seeded into collagen I-coated culture dishes then the adherent cells were stained, lysed and the optical densitometry was read. (F) The effect of tivozanib on ICAM-1 expression was measured by qRT-PCR. (G) The cells were treated with tivozanib then protein lysates were subjected to Western blotting and probed with ICAM-1 antibody.  $\beta$ -actin was used as the loading control. The concentrations of tivozanib were 5, 10 and 20  $\mu$ M. The blots are representative of three independent experiments with similar results. Data are given as mean  $\pm$  SD. Statistically significant values of \* $p$  < 0.05, \*\* $p$  < 0.01, and \*\*\* $p$  < 0.001 were determined compared with the control.



**Figure 5. Effects of tivozanib on activation of pertinent oncogenic pathways.** The cells were treated with tivozanib for 48 h then whole cell lysates were prepared and resolved by SDS PAGE. Samples were blotted for the phospho-form and re-probed for the respective total form of VEGFR2, STAT3, NF- $\kappa$ B p65, AKT and ERK1/2.  $\beta$ -actin was used as the loading control. The concentrations of tivozanib were 5, 10 and 20  $\mu$ M. The blots are representative of three independent experiments with similar results.

EGFR-directed therapies. For the combination therapy, the cells were pre-treated with tivozanib for 4 h, followed by treatment with anti-EGFR therapies including erlotinib, gefitinib and cetuximab for 48 h. The time-sequenced tivozanib-anti-EGFR therapy had a synergistic effect on growth inhibition and activation of caspase-3, an indicator of apoptosis (Fig. 6, Table 2, Supplementary Figs 4 and 5 and Supplementary Tables 3 and 4). These data suggest that VEGFR blockade by tivozanib enhances sensitivity to the EGFR-directed therapies in the EOC cells.

## Discussion

The VEGF family is aberrantly expressed in EOC<sup>9,49</sup>. High levels of VEGFA correlate with advanced tumour stage, ascites formation, distant metastases and poor overall survival<sup>50,51</sup>. Spannuth *et al* have demonstrated higher expression of VEGFR2 in malignant ovarian samples compared to benign or borderline tumours, which showed a correlation with tumour grade and aggressiveness<sup>39,52</sup>. Moreover, VEGFA suppresses immune-mediated anti-tumour responses in EOC<sup>53</sup>. Although these findings indicate that the VEGF/VEGFR loop promotes malignant progression in EOC, the role of this pathway in driving the chemoresistant disease is largely unknown.


Emerging data indicate that the VEGF ligands act as survival factors for tumour cells that express the receptors<sup>54–56</sup>. In colorectal cancer cells, VEGFA depletion reduces cell survival and enhances chemosensitivity via blockade of AKT and ERK1/2 pathways<sup>57</sup>. An autocrine VEGFA/VEGFR2 pathway opposes apoptosis in leukaemia cells through induction of the anti-apoptotic protein Bcl-2<sup>58</sup>. An angiogenic loop of VEGFC/VEGFR3 protects leukemic cells from pro-apoptotic effects of chemotherapy<sup>59</sup> and blockade of VEGFR3 induces chemosensitisation in EOC cells<sup>60</sup>. Consistent with this, our data demonstrate that high expression of VEGFR2 and VEGFC correlates with resistance to cisplatin and erlotinib, respectively. Collectively, these findings suggest that the VEGF family plays important roles in therapy resistance and blocking all the VEGF receptors may provide advantages over single-targeted therapies.

Abnormalities in cell cycle mediators such as cyclins, cyclin-dependent kinases (CDKs) and their inhibitors are thought to be early events in the pathogenesis of EOC and provide an unchecked growth advantage<sup>61</sup>. Deregulation of the G2/M regulatory proteins p21, cyclin B1 and Cdc25C correlates with poor survival in EOC<sup>62</sup>. Exogenous expression of p21, depletion of CCNB1 and shRNA suppression of CDC25C inhibit growth and induce apoptosis<sup>63–66</sup>. These findings suggest that the cell cycle regulatory network is a promising therapeutic target to halt growth and proliferation of EOC cells<sup>67,68</sup>. In line with this, the results of the present study show that VEGFR blockade by tivozanib retards proliferation of the chemoresistant EOC cells through a G2/M cell cycle arrest via up-regulation of p21 and down-modulation of cyclin B1 and Cdc25C.

EOC is a highly metastatic malignancy characterized by peritoneal dissemination. An essential step in the peritoneal spread of EOC is adhesion and implantation of the tumour cells to the mesothelial cells lining the peritoneum<sup>69</sup>. Cell adhesion molecules including ICAM-1 mediate the adhesion process<sup>42</sup>. Moreover, extracellular proteinases MMP-2 and uPA play central roles in mesothelial invasion and their blocking reduces peritoneal metastasis<sup>70–72</sup>. Evidence indicates that increasing EOC migration and invasion is a mechanism through which the VEGF family promotes peritoneal dissemination<sup>73</sup>. The findings of this study reveal that tivozanib reduces adhesive and invasive characteristics of the EOC cells through inhibition of ICAM-1, uPA and MMP-2 and suggest that it might have clinical applications in translational oncology to pre-empt peritoneal dissemination.

Elevated expression of VEGFA drives resistance to anti-EGFR therapies<sup>74</sup>. Acquired resistance of xenograft models of squamous cell carcinoma to anti-EGFR monoclonal antibodies associates with enhanced levels of VEGFA<sup>48</sup>. Moreover, increased expression of VEGFA contributes to development of gefitinib-resistant colon cancer cells, which is abrogated by treatment with a VEGFR2 inhibitor<sup>75</sup>. In the present study, we found that erlotinib-resistant EOC cells exhibit over-expression of VEGFC and pre-treatment with tivozanib synergistically enhanced erlotinib anti-proliferative activity. Altogether, these data suggest that VEGFR blockade by tivozanib induce sensitisation to the EGFR-directed therapies in the EOC cells.

Members of the Bcl-2 family of proteins play an essential role in chemosensitivity in EOC<sup>76,77</sup>. High levels of Bax correlate with increased response to paclitaxel chemotherapy and reduced risk of relapse<sup>78</sup>. ABT737, a Bcl-2



**Figure 6. Combined treatment with tivozanib and erlotinib results in anti-proliferative and pro-apoptotic synergism.** (A) The effect of the time-sequenced tivozanib-erlotinib therapy on cell proliferation was investigated by MTT assay and shown by IC<sub>50</sub> shift analysis. (B) Normalised isobolograms of combination of tivozanib (10 μM) and erlotinib (1, 2, 5, 10, 20 and 50 μM). The data were analysed using the CalcuSyn software. The connecting line represents additivity. Data points located below the line indicate a synergistic drug-drug interaction and data points above the line indicate an antagonistic drug-drug interaction. The numbers under the isobolograms indicate the doses of tivozanib and erlotinib in combination (C) The effect of combined tivozanib-erlotinib treatment on activation of caspase 3 was measured by a colorimetric caspase 3 activity assay. Data are given as mean ± SD. Statistically significant values of \**p* < 0.05, \*\**p* < 0.01, and \*\*\**p* < 0.001 were determined compared with the control.

family inhibitor, sensitises EOC cells to carboplatin and co-delivery of survivin shRNA and paclitaxel synergistically induces apoptosis<sup>79,80</sup>. Our findings indicate that tivozanib-induced sensitisation to the anti-EGFR therapies might be through down-regulation of the anti-apoptotic proteins survivin (encoded by *BIRC5*) and Bcl-2.

Taken together, our data suggest that the VEGF/VEGFR loop may have potential as a therapeutic target in the chemoresistant EOC and provide new insight into the mechanistic activities of tivozanib. Blockade of VEGF receptors by tivozanib reduced proliferative and invasive characteristics of the drug-resistant EOC cells. Combination of tivozanib with the EGFR-directed therapies displayed synergistic activity on cell growth inhibition and induction of apoptosis, suggesting that anti-VEGFR-targeted approaches induce sensitisation to the EGFR-directed therapies. Further *in vivo* studies are warranted to explore the anti-tumour activity of tivozanib alone or in combination with EGFR inhibitors in chemoresistant EOC.

## Materials and methods

**Antibodies and chemicals.** Antibodies were obtained as follows: AKT, p-AKT (Ser473; clone D9E), ERK1/2 and p-ERK1/2 (Thr202/Tyr204; clone 197G2), p-VEGFR2 (Tyr1175; clone 19A10), p-NF-κB p65 (Ser536; clone 93H1) (Cell Signalling Technology); VEGFR2 (clone A-3), STAT3 (clone C-20), p-STAT3 (clone B-7), NF-κB p65 (clone C-20), ICAM-1 (clone H-108), Bcl-2 (clone N-19), Bax (clone N-20), survivin (clone



Concentrations ( $\mu\text{M}$ )		fa	CI	DRI	
Tivozanib	Erlotinib			Tivozanib	Erlotinib
<b>OVCAR3</b>					
10	1	0.65	0.59	1.8	35.2
10	2	0.69	0.57	1.9	22.5
10	5	0.75	0.55	2.1	13.2
10	10	0.79	0.56	2.3	8.5
10	20	0.83	0.55	2.5	6.4
10	50	0.86	0.64	2.8	3.5
<b>SKOV3</b>					
10	1	0.41	0.54	2.1	17.3
10	2	0.44	0.5	2.5	10.5
10	5	0.49	0.46	3.4	6
10	10	0.52	0.49	4.3	3.9
10	20	0.54	0.66	4.9	2.2
10	50	0.58	1	6.5	1.2
<b>A2780CP</b>					
10	1	0.52	0.43	2.6	18.6
10	2	0.54	0.44	2.9	10
10	5	0.65	0.36	5	6.1
10	10	0.73	0.36	8	4.3
10	20	0.75	0.51	9.4	2.5
10	50	0.76	1.06	10.1	1

**Table 2. Combination index (CI) and dose reduction index (DRI) of tivozanib and erlotinib combination in OVCAR3, SKOV3 and A2780CP cells.** DRI represents the order of magnitude of dose reduction that is allowed in combination for a given degree of effect as compared with the dose of each drug alone. “fa” denotes fraction affected.

FL-142), p21 (clone C-19), c-Myc (clone 9E10), cyclin B1 (clone GNS1), Wee1 (clone C-20), Cdc25C (clone C-20) and  $\beta$ -actin (Santa Cruz Biotechnology).

Tivozanib and apatinib (a highly selective VEGFR-2 tyrosine kinase inhibitor) were purchased from AdooQ BioScience (Irvine, CA, USA) and were dissolved in DMSO. The final concentrations of DMSO did not exceed than 0.1% [v/v] in all the treatments. Erlotinib and gefitinib (EGFR small-molecule tyrosine kinase inhibitors) were obtained from ChemieTek (Indianapolis, IN, USA). Cetuximab (a ligand-blocking anti-EGFR mAb), cisplatin and doxorubicin (DNA-damaging drugs), paclitaxel (a taxane inhibitor of microtubule disassembly), vincristine (a mitosis-blocking agent), carboplatin (an alkylating agent) and gemcitabine (a nucleoside analogue which inhibits DNA synthesis) were purchased from the pharmacy of Shariati hospital (Tehran, Iran). Poly-hydroxyethylmethacrylate polymer (poly-HEMA) was obtained from Santa Cruz Biotechnology. Human recombinant VEGFC (rVEGFC) was purchased from Peprotech.

**Human ovarian carcinoma cell lines.** Human ovarian carcinoma cell lines were obtained from National Cell Bank of Iran (NCBI; Tehran, Iran). These include A2780CP (adenocarcinoma), A2780S (adenocarcinoma), Caov4 (originated from metastatic fallopian tube mass), OVCAR3 (originated from ovarian cancer ascites) and SKOV3 (originated from ovarian cancer ascites)<sup>81</sup>. All the cell lines were authenticated by STR profiling using Cell ID™ system (Promega) and were routinely checked for mycoplasma infection. Cell cultures were maintained at 37 °C in 5% CO<sub>2</sub> in a humidified incubator and cultured according to the NCBI recommendations.

**Cytotoxicity assays.** The EOC cells in logarithmic growth phase were plated ( $2 \times 10^3$  cells/well) in 96-well plates. After incubation at 37 °C for 24 h, the cultures were exposed to desired concentrations of the chemotherapeutics for 48 h and the proportion of viable cells was determined by MTT assay. Vehicle-treated cells were used as the control group. Cytotoxicity was shown as IC<sub>50</sub> values calculated from full dose–response curves. Synergism was determined by calculation of the combination index (CI) according to Chou and Talalay<sup>82</sup> using the CalcuSyn software (Biosoft, Cambridge, UK). CI < 1, CI = 1, and CI > 1 represent synergism, additive effects, and antagonism of the 2 drugs, respectively.

**Crystal violet staining.** The cells were plated at a density of  $6 \times 10^4$  cells in 6-well plates and treated with the drugs for 48 h. The cultures were then washed with PBS, fixed with ice-cold methanol and stained with crystal violet (0.5% w/v). The images were acquired with an inverted microscope.

**Colony formation assay.** Cells were seeded into 6-well plates with a density of 200–400 cell/well. After 12 h, the cells were treated with increasing concentrations of tivozanib for 48 h. The media was changed to drug-free media and the cells were incubated at 37 °C in 5% CO<sub>2</sub> for 10 d. The cultures were fixed in ice-cold methanol for 20 min at room temperature and stained with crystal violet solution (0.5% w/v). The colonies were counted by

naked eyes and the surviving fraction (SF) was estimated as: (mean colony counts)/(cells plated)  $\times$  (plating efficiency), where plating efficiency (PE) was determined as (mean colony counts)/(cells plated for controls).

**Anoikis resistance assay.** Poly-HEMA was solubilized in 95% ethanol (20 mg/mL) and then 25  $\mu$ L of this solution was placed in 96-well plates and dried in a tissue culture hood. Anoikis was induced by culturing  $5 \times 10^3$  cells on poly-HEMA coated plates in the medium containing increasing concentrations of tivozanib. The cell suspension cultures were maintained in a humidified 5% CO<sub>2</sub> incubator at 37 °C for 48 h. One hundred  $\mu$ L of MTT solution (0.5 mg/mL) was added to each well and the cells were further incubated at 37 °C for 2 h. The precipitated formazan was dissolved in DMSO and the optical densitometry was measured at 570 nm.

**Analysis of gene expression by quantitative reverse transcription-PCR.** The quantitative reverse transcription-PCR (qRT-PCR) analysis was performed on a StepOne Plus instrument (Applied Biosystems) using RealQ-PCR Master Mix kit (Ampliqon, Copenhagen, Denmark). Thermal cycling conditions involved an activation step for 15 min at 95 °C followed by 40 cycles including a denaturation step for 15 s at 95 °C and a combined annealing/extension step for 1 min at 60 °C. The primers used are listed in Supplementary Table 2. The target gene expression levels were normalized to hypoxanthine phosphoribosyl transferase1 (*HPRT1*) levels in the same reaction. For calculations,  $2^{-\Delta\Delta C_T}$  formula was used, with  $\Delta\Delta C_T = (C_{T\text{Target}} - C_{T\text{HPRT1}})$  experimental sample  $- (C_{T\text{Target}} - C_{T\text{HPRT1}})$  control samples, where  $C_T$  is cycle threshold.

**Western blot analysis.** Total protein extracts were prepared in RIPA buffer (50 mM Tris-HCl, pH 8.0, 150 mM NaCl, 1.0% NP-40, 0.5% sodium deoxycholate and 0.1% SDS) containing protease and phosphatase inhibitors (Roche Molecular Biochemicals) for 30 min at 4 °C. Fifty to hundred  $\mu$ g of lysate was resolved by SDS-PAGE, transferred to PVDF membrane (Membrane Solutions, TX, USA) then probed with primary and horseradish peroxidase (HRP)-conjugated secondary antibodies (Sigma).  $\beta$ -actin was used as the loading control and proteins were detected using a BM chemiluminescence detection kit (Roche Molecular Biochemicals).

**Cell cycle analysis.** Propidium iodide staining was conducted for detection of DNA content. Following tivozanib treatment for 48 h, harvested cells were washed in ice-cold PBS, fixed in 70% ethanol and stored at  $-20$  °C overnight. Vehicle-treated cells were used as the control group. The cell pellets were then incubated with RNase A (100  $\mu$ g/mL) (Sigma), propidium iodide (50  $\mu$ g/mL) (Sigma) and 0.05% Triton X-100. Cellular DNA content was analyzed on a FACSCalibur (BD Bioscience) flow cytometer equipped with CellQuest Pro software.

**Zymography.** Equal amounts of secreted protein from the conditioned media of tivozanib-treated and vehicle-treated cells were applied to 10% polyacrylamide gels copolymerized with 1 mg/mL gelatin A (Sigma). After electrophoresis, gels were rinsed in 2.5% Triton X-100 ( $2 \times 15$  min) to remove SDS, followed by incubation at 37 °C overnight in incubation buffer (0.15 M NaCl, 10 mM CaCl<sub>2</sub>, 0.02% NaN<sub>3</sub> in 50 mM Tris-HCl, pH 7.5). The gels were then stained (0.5% Coomassie Brilliant Blue) and destained with 7% methanol and 5% acetic acid. Areas of enzymatic activity appeared as clear bands over the dark background.

**Urokinase-type plasminogen activator activity assay.** Urokinase-type plasminogen activator (uPA) activity was assayed with a uPA-specific chromogenic substrate according to the manufacturer's instructions (Millipore). Equal amounts of protein from the uPA-containing conditioned media were added to the chromogenic substrate and incubated at 37 °C for 1 h. The samples were then read at 405 nm.

**Cell adhesion.** After treatment with tivozanib for 48 h, the cells were counted and equal cell number from both tivozanib-treated and vehicle-treated groups was seeded in collagen I-coated 60 mm dishes (Biocoat Cell Environments; Becton Dickinson). Following incubation for 15 min at 37 °C, the cells were washed twice with cold PBS, stained with 0.5% crystal violet, lysed with 30% acetic acid and the optical densitometry was measured at 590 nm.

**Transwell cell migration and invasion.** Cell migration and invasion assays were carried out as described earlier<sup>83</sup>.

**Caspase 3 activity assay.** To assess induction of apoptosis, a colorimetric caspase 3 activity assay was employed according to the manufacturer's protocol (Sigma). Briefly, cell lysates from both adherent and floating cells were centrifuged at  $20000 \times g$  for 10 min. Twenty  $\mu$ g of the supernatant was incubated with 85  $\mu$ L of assay buffer plus 10  $\mu$ L of caspase 3 substrate acetyl-Asp-Glu-Val-Asp p-nitroanilide (Ac-DEVD-pNA) in a 96-well plate at 37 °C for 12 h. The samples were then read at 405 nm in an ELISA reader.

**Statistical analysis.** All data were evaluated in triplicate against vehicle-treated control cells and collected from three independent experiments. Data were graphed and analysed using GraphPad Prism Software 6.0 using one-way ANOVA and the unpaired two-tailed Student's *t* test. All data are presented as mean  $\pm$  standard deviation (SD).

## References

1. Siegel, R. L., Miller, K. D. & Jemal, A. Cancer statistics, 2016. *CA: a cancer journal for clinicians* **66**, 7–30 (2016).
2. Korkmaz, T., Seber, S. & Basaran, G. Review of the current role of targeted therapies as maintenance therapies in first and second line treatment of epithelial ovarian cancer; In the light of completed trials. *Critical reviews in oncology/hematology* **98**, 180–188 (2016).
3. Dinh, P., Harnett, P., Piccart-Gebhart, M. J. & Awada, A. New therapies for ovarian cancer: cytotoxics and molecularly targeted agents. *Critical reviews in oncology/hematology* **67**, 103–112, doi: 10.1016/j.critrevonc.2008.01.012 (2008).

4. Ferrandina, G. *et al.* Phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in progressive or recurrent ovarian cancer. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology* **26**, 890–896, doi: 10.1200/JCO.2007.13.6606 (2008).
5. Hicklin, D. J. & Ellis, L. M. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology* **23**, 1011–1027, doi: 10.1200/JCO.2005.06.081 (2005).
6. Spannuth, W. A., Sood, A. K. & Coleman, R. L. Angiogenesis as a strategic target for ovarian cancer therapy. *Nat Clin Pract Oncol* **5**, 194–204, doi: 10.1038/ncponc1051 (2008).
7. Vecchione, A. *et al.* A microRNA signature defines chemoresistance in ovarian cancer through modulation of angiogenesis. *Proceedings of the National Academy of Sciences of the United States of America* **110**, 9845–9850, doi: 10.1073/pnas.1305472110 (2013).
8. Santulli, G. *et al.* *In vivo* properties of the proangiogenic peptide QK. *J Transl Med* **7**, 41, doi: 10.1186/1479-5876-7-41 (2009).
9. Boocock, C. A. *et al.* Expression of Vascular Endothelial Growth Factor and Its Receptors and KDR in Ovarian Carcinoma. *Journal of the National Cancer Institute* **87**, 506–516 (1995).
10. Decio, A. *et al.* Vascular endothelial growth factor c promotes ovarian carcinoma progression through paracrine and autocrine mechanisms. *Am J Pathol* **184**, 1050–1061, doi: 10.1016/j.ajpath.2013.12.030 (2014).
11. Olson, T. A., Mohanraj, D., Carson, L. F. & Ramakrishnan, S. Vascular permeability factor gene expression in normal and neoplastic human ovaries. *Cancer research* **54**, 276–280 (1994).
12. Nishida, N. *et al.* Vascular endothelial growth factor C and vascular endothelial growth factor receptor 2 are related closely to the prognosis of patients with ovarian carcinoma. *Cancer* **101**, 1364–1374 (2004).
13. Fagotti, A. *et al.* Peritoneal carcinosis of ovarian origin. *World J Gastrointest Oncol* **2**, 102–108 (2010).
14. Mesiano, S., Ferrara, N. & Jaffe, R. B. Role of vascular endothelial growth factor in ovarian cancer: inhibition of ascites formation by immunoneutralization. *The American journal of pathology* **153**, 1249–1256 (1998).
15. Monk, B. J., Dalton, H., Farley, J. H., Chase, D. M. & Benjamin, I. Antiangiogenic agents as a maintenance strategy for advanced epithelial ovarian cancer. *Critical reviews in oncology/hematology* **86**, 161–175 (2013).
16. Eskander, R. N. & Tewari, K. S. Incorporation of anti-angiogenesis therapy in the management of advanced ovarian carcinoma—mechanistics, review of phase III randomized clinical trials, and regulatory implications. *Gynecologic oncology* **132**, 496–505 (2014).
17. McLachlan, J., Lima, J. P., Dumas, L. & Banerjee, S. Targeted agents and combinations in ovarian cancer: where are we now? *Expert Rev Anticancer Ther* **16**, 441–454, doi: 10.1586/14737140.2016.1162101 (2016).
18. Perren, T. J. *et al.* A phase 3 trial of bevacizumab in ovarian cancer. *New England Journal of Medicine* **365**, 2484–2496 (2011).
19. Burger, R. A. *et al.* Incorporation of bevacizumab in the primary treatment of ovarian cancer. *New England Journal of Medicine* **365**, 2473–2483 (2011).
20. Pujade-Lauraine, E. *et al.* Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: the AURELIA open-label randomized phase III trial. *Journal of Clinical Oncology* **32**, 1302–1308 (2014).
21. Burger, R. A., Sill, M. W., Monk, B. J., Greer, B. E. & Sorosky, J. I. Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology* **25**, 5165–5171, doi: 10.1200/JCO.2007.11.5345 (2007).
22. Graybill, W., Sood, A. K., Monk, B. J. & Coleman, R. L. State of the science: Emerging therapeutic strategies for targeting angiogenesis in ovarian cancer. *Gynecologic oncology* **138**, 223–226, doi: 10.1016/j.ygyno.2015.07.008 (2015).
23. De Luca, A. & Normanno, N. Tivozanib, a pan-VEGFR tyrosine kinase inhibitor for the potential treatment of solid tumors. *IDrugs: the investigational drugs journal* **13**, 636–645 (2010).
24. Jayson, G. C., Kohn, E. C., Kitchener, H. C. & Ledermann, J. A. Ovarian cancer. *The Lancet* **384**, 1376–1388 (2014).
25. Marchetti, C. *et al.* First-line treatment of advanced ovarian cancer: current research and perspectives. *Expert review of anticancer therapy* **10**, 47–60 (2010).
26. Eskens, F. A. *et al.* Biologic and clinical activity of tivozanib (AV-951, KRN-951), a selective inhibitor of VEGF receptor-1,-2, and-3 tyrosine kinases, in a 4-week-on, 2-week-off schedule in patients with advanced solid tumors. *Clinical Cancer Research* **17**, 7156–7163 (2011).
27. Marchetti, C. *et al.* Tyrosine-kinases inhibitors in recurrent platinum-resistant ovarian cancer patients. *Cancer treatment reviews* **42**, 41–46 (2016).
28. Lee, M. J. *et al.* Sequential application of anticancer drugs enhances cell death by rewiring apoptotic signaling networks. *Cell* **149**, 780–794 (2012).
29. Frisch, S. M. & Ruoslahti, E. Integrins and anoikis. *Curr Opin Cell Biol* **9**, 701–706 (1997).
30. Sher, I., Adham, S. A., Petrik, J. & Coomber, B. L. Autocrine VEGF-A/KDR loop protects epithelial ovarian carcinoma cells from anoikis. *International journal of cancer. Journal international du cancer* **124**, 553–561, doi: 10.1002/ijc.23963 (2009).
31. Trapp, E. K. *et al.* Abstract P4-01-16: Detection of EMT, anoikis and stem cell markers in metastatic breast cancer patients under different lines of treatment. *Cancer research* **75**, P4-01-16–P04-01-16 (2015).
32. Chow, J. P. H. & Poon, R. Y. C. The CDK1 inhibitory kinase MYT1 in DNA damage checkpoint recovery. *Oncogene* **32**, 4778–4788 (2013).
33. Boutros, R., Lobjois, V. & Ducommun, B. CDC25 phosphatases in cancer cells: key players? Good targets? *Nature Reviews Cancer* **7**, 495–507 (2007).
34. Antoni, L., Sodha, N., Collins, I. & Garrett, M. D. CHK2 kinase: cancer susceptibility and cancer therapy—two sides of the same coin? *Nature Reviews Cancer* **7**, 925–936 (2007).
35. Graves, L. E. *et al.* Proinvasive properties of ovarian cancer ascites-derived membrane vesicles. *Cancer research* **64**, 7045–7049 (2004).
36. Zhang, A. *et al.* Enhanced *in vitro* invasiveness of ovarian cancer cells through up-regulation of VEGF and induction of MMP-2. *Oncology reports* **15**, 831–836 (2006).
37. So, J., Wang, F.-q., Navari, J., Schreher, J. & Fishman, D. A. LPA-induced epithelial ovarian cancer (EOC) *in vitro* invasion and migration are mediated by VEGF receptor-2 (VEGF-R2). *Gynecologic oncology* **97**, 870–878 (2005).
38. Belotti, D. *et al.* Matrix metalloproteinases (MMP9 and MMP2) induce the release of vascular endothelial growth factor (VEGF) by ovarian carcinoma cells implications for ascites formation. *Cancer research* **63**, 5224–5229 (2003).
39. Wang, F.-q., Barfield, E., Dutta, S., Pua, T. & Fishman, D. A. VEGFR-2 silencing by small interference RNA (siRNA) suppresses LPA-induced epithelial ovarian cancer (EOC) invasion. *Gynecologic oncology* **115**, 414–423 (2009).
40. Huang, K.-J. & Sui, L.-H. The relevance and role of vascular endothelial growth factor C, matrix metalloproteinase-2 and E-cadherin in epithelial ovarian cancer. *Medical oncology* **29**, 318–323 (2012).
41. Slack-Davis, J. K., Atkins, K. A., Harrer, C., Hershey, E. D. & Conaway, M. Vascular cell adhesion molecule-1 is a regulator of ovarian cancer peritoneal metastasis. *Cancer research* **69**, 1469–1476 (2009).
42. Gardner, M. J., Jones, L. M., Catterall, J. B. & Turner, G. A. Expression of cell adhesion molecules on ovarian tumour cell lines and mesothelial cells, in relation to ovarian cancer metastasis. *Cancer letters* **91**, 229–234 (1995).
43. Roland, C. L., Harken, A. H., Sarr, M. G. & Barnett, C. C. ICAM-1 expression determines malignant potential of cancer. *Surgery* **141**, 705–707 (2007).

44. Mason, J. C. *et al.* Decay-accelerating Factor Induction on Vascular Endothelium by Vascular Endothelial Growth Factor (VEGF) Is Mediated via a VEGF Receptor-2 (VEGF-R2)-and Protein Kinase C- $\alpha$ / $\epsilon$  (PKC $\alpha$ / $\epsilon$ )-dependent Cytoprotective Signaling Pathway and Is Inhibited by Cyclosporin A. *Journal of Biological Chemistry* **279**, 41611–41618 (2004).
45. Chen, H., Ye, D., Xie, X., Chen, B. & Lu, W. VEGF, VEGFRs expressions and activated STATs in ovarian epithelial carcinoma. *Gynecologic oncology* **94**, 630–635 (2004).
46. Trinh, X. B. *et al.* The VEGF pathway and the AKT/mTOR/p70S6K1 signalling pathway in human epithelial ovarian cancer. *British journal of cancer* **100**, 971–978 (2009).
47. Fischer-Colbrie, J. *et al.* EGFR and steroid receptors in ovarian carcinoma: comparison with prognostic parameters and outcome of patients. *Anticancer research* **17**, 613–619 (1996).
48. Vilorio-Petit, A. *et al.* Acquired resistance to the antitumor effect of epidermal growth factor receptor-blocking antibodies *in vivo* A role for altered tumor angiogenesis. *Cancer research* **61**, 5090–5101 (2001).
49. Inan, S. *et al.* Immunolocalizations of VEGF, its receptors flt-1, KDR and TGF- $\beta$ 's in epithelial ovarian tumors. *Histol Histopathol* **21**, 1055–1064 (2006).
50. Rudlowski, C. *et al.* Prognostic significance of vascular endothelial growth factor expression in ovarian cancer patients: a long-term follow-up. *International Journal of Gynecological Cancer* **16**, 183–189 (2006).
51. Yu, L., Deng, L., Li, J., Zhang, Y. & Hu, L. The prognostic value of vascular endothelial growth factor in ovarian cancer: a systematic review and meta-analysis. *Gynecologic oncology* **128**, 391–396 (2013).
52. Spannuth, W. A. *et al.* Functional significance of VEGFR-2 on ovarian cancer cells. *International journal of cancer* **124**, 1045–1053 (2009).
53. Tiper, I. V. *et al.* VEGF Potentiates GD3-Mediated Immunosuppression by Human Ovarian Cancer Cells. *Clinical cancer research : an official journal of the American Association for Cancer Research* **22**, 4249–4258, doi: 10.1158/1078-0432.CCR-15-2518 (2016).
54. Calvani, M., Trisciuglio, D., Bergamaschi, C., Shoemaker, R. H. & Melillo, G. Differential involvement of vascular endothelial growth factor in the survival of hypoxic colon cancer cells. *Cancer research* **68**, 285–291 (2008).
55. Pidgeon, G. P., Barr, M. P., Harmey, J. H., Foley, D. A. & Bouchier-Hayes, D. J. Vascular endothelial growth factor (VEGF) upregulates BCL-2 and inhibits apoptosis in human and murine mammary adenocarcinoma cells. *British journal of cancer* **85**, 273–278, doi: 10.1054/bjoc.2001.1876 (2001).
56. Hua, K.-T. *et al.* Vascular endothelial growth factor-C modulates proliferation and chemoresistance in acute myeloid leukemic cells through an endothelin-1-dependent induction of cyclooxygenase-2. *Biochimica et Biophysica Acta (BBA)-Molecular Cell Research* **1843**, 387–397 (2014).
57. Bhattacharya, R. *et al.* Intracrine VEGF Signaling Mediates the Activity of Prosurvival Pathways in Human Colorectal Cancer Cells. *Cancer research* **76**, 3014–3024, doi: 10.1158/0008-5472.CAN-15-1605 (2016).
58. Dias, S., Shmelkov, S. V., Lam, G. & Rafii, S. VEGF165 promotes survival of leukemic cells by Hsp90-mediated induction of Bcl-2 expression and apoptosis inhibition. *Blood* **99**, 2532–2540 (2002).
59. Dias, S., Choy, M., Alitalo, K. & Rafii, S. Vascular endothelial growth factor (VEGF)-C signaling through FLT-4 (VEGFR-3) mediates leukemic cell proliferation, survival, and resistance to chemotherapy. *Blood* **99**, 2179–2184 (2002).
60. Lim, J., Yang, K., Taylor-Harding, B., Wiedemeyer, W. R. & Buckanovich, R. J. VEGFR3 inhibition chemosensitizes ovarian cancer stemlike cells through down-regulation of BRCA1 and BRCA2. *Neoplasia* **16**, 343–353. e342 (2014).
61. Landen, C. N., Birrer, M. J. & Sood, A. K. Early events in the pathogenesis of epithelial ovarian cancer. *Journal of Clinical Oncology* **26**, 995–1005 (2008).
62. Hashiguchi, Y. *et al.* Alteration of cell cycle regulators correlates with survival in epithelial ovarian cancer patients. *Human pathology* **35**, 165–175 (2004).
63. Crombez, L. *et al.* Targeting cyclin B1 through peptide-based delivery of siRNA prevents tumour growth. *Nucleic acids research* **37**, 4559–4569, doi: 10.1093/nar/gkp451 (2009).
64. Davies, S. *et al.* High incidence of ErbB3, ErbB4, and MET expression in ovarian cancer. *International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists* **33**, 402–410, doi: 10.1097/PGP.0000000000000081 (2014).
65. Qin, L. F. & Ng, I. O. Exogenous expression of p21 WAF1/CIP1 exerts cell growth inhibition and enhances sensitivity to cisplatin in hepatoma cells. *Cancer letters* **172**, 7–15 (2001).
66. Wei, S. *et al.* A critical role for phosphatase haplodeficiency in the selective suppression of deletion 5q MDS by lenalidomide. *Proceedings of the National Academy of Sciences* **106**, 12974–12979 (2009).
67. Ye, Q., Lei, L. & Aili, A. Identification of potential targets for ovarian cancer treatment by systematic bioinformatics analysis. *European journal of gynaecological oncology* **36**, 283–289 (2014).
68. Urzua, U., Ampuero, S., Roby, K. F., Owens, G. A. & Munroe, D. J. Dysregulation of mitotic machinery genes precedes genome instability during spontaneous pre-malignant transformation of mouse ovarian surface epithelial cells. *BMC Genomics* **17**, 728, doi: 10.1186/s12864-016-3068-5 (2016).
69. Lengyel, E. Ovarian cancer development and metastasis. *The American journal of pathology* **177**, 1053–1064 (2010).
70. Kenny, H. A., Kaur, S., Coussens, L. M. & Lengyel, E. The initial steps of ovarian cancer cell metastasis are mediated by MMP-2 cleavage of vitronectin and fibronectin. *The Journal of clinical investigation* **118**, 1367–1379 (2008).
71. Kenny, H. A. & Lengyel, E. MMP-2 functions as an early response protein in ovarian cancer metastasis. *Cell cycle* **8**, 683–688 (2009).
72. Wilhelm, O., Schmitt, M., Höhl, S., Senekowitsch, R. & Graeff, H. Antisense inhibition of urokinase reduces spread of human ovarian cancer in mice. *Clinical & experimental metastasis* **13**, 296–302 (1995).
73. Moghaddam, S. M., Amini, A., Morris, D. L. & Pourgholami, M. H. Significance of vascular endothelial growth factor in growth and peritoneal dissemination of ovarian cancer. *Cancer and Metastasis Reviews* **31**, 143–162 (2012).
74. Vallböhmer, D. *et al.* Molecular determinants of cetuximab efficacy. *Journal of Clinical Oncology* **23**, 3536–3544 (2005).
75. Ciardello, F. *et al.* Antitumor activity of ZD6474, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in human cancer cells with acquired resistance to anti-epidermal growth factor receptor therapy. *Clinical Cancer Research* **10**, 784–793 (2004).
76. Eliopoulos, A. G. *et al.* The control of apoptosis and drug resistance in ovarian cancer: influence of p53 and Bcl-2. *Oncogene* **11**, 1217–1228 (1995).
77. Beale, P. J., Rogers, P., Boxall, F., Sharp, S. Y. & Kelland, L. R. BCL-2 family protein expression and platinum drug resistance in ovarian carcinoma. *British journal of cancer* **82**, 436–440, doi: 10.1054/bjoc.1999.0939 (2000).
78. Tai, Y. T. *et al.* BAX protein expression and clinical outcome in epithelial ovarian cancer. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology* **16**, 2583–2590 (1998).
79. Witham, J. *et al.* The Bcl-2/Bcl-XL family inhibitor ABT-737 sensitizes ovarian cancer cells to carboplatin. *Clinical cancer research : an official journal of the American Association for Cancer Research* **13**, 7191–7198, doi: 10.1158/1078-0432.CCR-07-0362 (2007).
80. Hu, Q. *et al.* Synergistic treatment of ovarian cancer by co-delivery of survivin shRNA and paclitaxel via supramolecular micellar assembly. *Biomaterials* **33**, 6580–6591 (2012).
81. Jacob, F., Nixdorf, S., Hacker, N. F. & Heinzlmann-Schwarz, V. A. Reliable *in vitro* studies require appropriate ovarian cancer cell lines. *Journal of ovarian research* **7**, 60, doi: 10.1186/1757-2215-7-60 (2014).
82. Chou, T. C. Drug combination studies and their synergy quantification using the Chou-Talalay method. *Cancer research* **70**, 440–446, doi: 10.1158/0008-5472.CAN-09-1947 (2010).
83. Momeny, M. *et al.* Heregulin-HER3-HER2 signaling promotes matrix metalloproteinase-dependent blood-brain-barrier transendothelial migration of human breast cancer cell lines. *Oncotarget* **6**, 3932–3946, doi: 10.18632/oncotarget.2846 (2015).

## Acknowledgements

Research reported in this publication was supported by Elite Researcher Grant Committee under award number [943594] from National Institute for Medical Research Development (NIMAD), Tehran, Iran and also a grant from Haematology/oncology and Stem Cell Transplantation Research Centre, Shariati hospital, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran. Technical assistance of Ms. Roghieh Koochi Ortakand is acknowledged.

## Author Contributions

M.M. designed the research; M.M., Z.S., G.Z., F.M., H.E., H.Y., S.M., E.M.P. and F.B. conducted the research; M.M., A.P., L.D., D.B., M.G., S.M.T., A.R.D., M.Y., K.A. and A.G. analysed the data; M.M. wrote the paper; S.H.G. had primary responsibility for the final content. All authors have reviewed and approved the final manuscript.

## Additional Information

**Supplementary information** accompanies this paper at <http://www.nature.com/srep>

**Competing Interests:** The authors declare no competing financial interests.

**How to cite this article:** Momeny, M. *et al.* Anti-tumour activity of tivozanib, a pan-inhibitor of VEGF receptors, in therapy-resistant ovarian carcinoma cells. *Sci. Rep.* 7, 45954; doi: 10.1038/srep45954 (2017).

**Publisher's note:** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.



This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>

© The Author(s) 2017